Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + cytarabine for newly treated secondary acute myeloid leukemia
ChiCTR2300076618Phase 4Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Composite complete remission rate. Started Oct 2023; status: completed.
02
Drugs
mitoxantronecytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2300076618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076618.